Abivax SA vs Suzhou Zelgen Biopharmaceuticals: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Abivax SA (ABVX.PA)

Q2 202617 Jun – 1 Jul 2026

▲3▼1

Abivax Soars on Strong Phase 3 Data, Analyst Upgrade, and $800M Raise

Positive Phase 3 Data Drives Stock Surge Abivax reported positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission and 34.5% endoscopic remission at Week 44. This strong efficacy in hard-to-treat patients boosts confidence in the drug's approvability, pushing the stock up 27%.
This is the core positive catalyst that directly lifted the stock and improved the drug's outlook.
Jefferies Upgrade Eases Safety Concerns Jefferies upgraded Abivax to Buy and raised its price target to $158, citing that updated Phase 3 data alleviated concerns over previously reported malignancy cases. The brokerage believes the safety issue is manageable and not a major regulatory hurdle, reinforcing the investment case.
This analyst action reflects and amplifies the positive data, providing a second driver for the stock's rise.
Upsized $800M Offering Extends Cash Runway Abivax priced an upsized $800 million public offering of ADSs at $125 per share, extending its cash runway into Q2 2029. The funds will support commercialization of obefazimod and clinical development, removing near-term financing risk and enabling the company to execute its strategy.
This capital raise strengthens the balance sheet and supports future growth, a key positive for the stock.
Schall Law Firm Investigation Adds Regulatory Overhang The Schall Law Firm is investigating Abivax for potential securities law violations related to undisclosed malignancy cases in the obefazimod trial. This legal scrutiny could lead to fines or reputational damage, weighing on the stock, though the recent positive data may mitigate the impact.
This is a negative factor that could pressure the stock, providing a balanced view of risks.

June 202617 Jun – 1 Jul 2026

▲3▼1

Abivax Soars on Strong Phase 3 Data, Analyst Upgrade, and $800M Raise

Positive Phase 3 Data Drives Stock Surge Abivax reported positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission and 34.5% endoscopic remission at Week 44. This strong efficacy in hard-to-treat patients boosts confidence in the drug's approvability, pushing the stock up 27%.
This is the core positive catalyst that directly lifted the stock and improved the drug's outlook.
Jefferies Upgrade Eases Safety Concerns Jefferies upgraded Abivax to Buy and raised its price target to $158, citing that updated Phase 3 data alleviated concerns over previously reported malignancy cases. The brokerage believes the safety issue is manageable and not a major regulatory hurdle, reinforcing the investment case.
This analyst action reflects and amplifies the positive data, providing a second driver for the stock's rise.
Upsized $800M Offering Extends Cash Runway Abivax priced an upsized $800 million public offering of ADSs at $125 per share, extending its cash runway into Q2 2029. The funds will support commercialization of obefazimod and clinical development, removing near-term financing risk and enabling the company to execute its strategy.
This capital raise strengthens the balance sheet and supports future growth, a key positive for the stock.
Schall Law Firm Investigation Adds Regulatory Overhang The Schall Law Firm is investigating Abivax for potential securities law violations related to undisclosed malignancy cases in the obefazimod trial. This legal scrutiny could lead to fines or reputational damage, weighing on the stock, though the recent positive data may mitigate the impact.
This is a negative factor that could pressure the stock, providing a balanced view of risks.

Latest17 Jun – 1 Jul 2026

▲3▼1

Abivax Soars on Strong Phase 3 Data, Analyst Upgrade, and $800M Raise

Positive Phase 3 Data Drives Stock Surge Abivax reported positive Phase 3 ABTECT Maintenance Part 2 results for obefazimod in refractory ulcerative colitis, showing 37.2% clinical remission and 34.5% endoscopic remission at Week 44. This strong efficacy in hard-to-treat patients boosts confidence in the drug's approvability, pushing the stock up 27%.
This is the core positive catalyst that directly lifted the stock and improved the drug's outlook.
Jefferies Upgrade Eases Safety Concerns Jefferies upgraded Abivax to Buy and raised its price target to $158, citing that updated Phase 3 data alleviated concerns over previously reported malignancy cases. The brokerage believes the safety issue is manageable and not a major regulatory hurdle, reinforcing the investment case.
This analyst action reflects and amplifies the positive data, providing a second driver for the stock's rise.
Upsized $800M Offering Extends Cash Runway Abivax priced an upsized $800 million public offering of ADSs at $125 per share, extending its cash runway into Q2 2029. The funds will support commercialization of obefazimod and clinical development, removing near-term financing risk and enabling the company to execute its strategy.
This capital raise strengthens the balance sheet and supports future growth, a key positive for the stock.
Schall Law Firm Investigation Adds Regulatory Overhang The Schall Law Firm is investigating Abivax for potential securities law violations related to undisclosed malignancy cases in the obefazimod trial. This legal scrutiny could lead to fines or reputational damage, weighing on the stock, though the recent positive data may mitigate the impact.
This is a negative factor that could pressure the stock, providing a balanced view of risks.

Suzhou Zelgen Biopharmaceuticals Co Ltd (688266.CG)

Q3 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

August 202621 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.

Latest21 Jul – 21 Sep 2026

▲4

Zelgen turns profitable, lands AbbVie deal and new drug filings

First-ever half-year profit on 1.2 billion yuan revenue Zelgen reported about 640 million yuan first-half net profit, its first half-year profit ever, on revenue up 220.88% to 1.205 billion yuan. Most came from licensing payments, but product sales also rose 44.3% as insurance-covered drugs sold more. Profitability supports the share price.
The profit turnaround is the core fundamental change behind the stock's re-rating.
AbbVie overseas licensing partnership Zelgen signed a strategic partnership with global drugmaker AbbVie for overseas licensing of its products. A big foreign partner can bring cash, validation and access to overseas markets, which raises expectations for future revenue and supports the stock.
A major global partnership is a new growth catalyst that directly lifts investor expectations.
New indication filing accepted by NMPA China's drug regulator accepted Zelgen's marketing application for a new use of injectable human thyrotropin beta (Zesuning), for thyroid cancer patients after surgery. Acceptance moves the product closer to approval, adding a future sales stream and helping the stock.
Regulatory progress on an existing product is a concrete new pipeline milestone.
Fund buying and friendlier innovative-drug rules Star manager Zhu Shaoxing's fund added Zelgen to its top ten holdings, a sign of rising institutional demand. Separately, the NMPA is strengthening pre-guidance and market exclusivity for innovative drugs, and Zelgen rose with a sector ETF. Both support the price.
Institutional buying and supportive regulation are fresh demand and policy tailwinds.